CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01134575

Last updated date
Study Location
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Lymphoblastic Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Previously treated ALL (including Burkitt's lymphoma and lymphoblastic lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration. At least 10 patients in Salvage 1-2 will be treated to assess anti-ALL response more precisely.

2. Age 16 years or older. Pediatric patients (<16 years old) will be allowed into the study after safety is established, that is at least 10 adult patients having received 1 or more cycles each.

3. Zubrod performance status 0-3.

4. Adequate liver function (bilirubin

5. Male and female patients who are of childbearing potential agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy. Female patients need a negative serum or urine pregnancy test within 14 days of study start (applies only if patient is of childbearing potential. Non-childbearing is defined as >/= 1 year postmenopausal or surgically sterilized).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patient with active heart disease (NYHA class >/= 3 as assessed by history and
physical examination).


2. Patients with a cardiac ejection fraction (as measured by either Radionuclide
angiography (MUGA) or echocardiogram) < 45% are excluded.


3. Patients who receive other chemotherapy. Patients must have been off previous therapy
for >/= 2 weeks and must have recovered from acute toxicity (to grade 1 or less) of
all previous therapy prior to enrollment (consent signing). (Concurrent therapy for
central nervous system [CNS] prophylaxis or treatment for CNS relapse is permitted).
Treatment may start earlier if necessitated by the patient's medical condition (e.g.
rapidly progressive disease) following discussion with the Principal Investigator.


4. Prior allogeneic stem cell transplant in previous 4 months.


5. Peripheral lymphoblasts > 50 x 10^9/L.


6. Pregnant and breast-feeding patients are excluded.


7. Patients with known hepatitis B are excluded.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Lymphoblastic LeukemiaInotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
NCT03913559
  1. Memphis, Tennessee
ALL GENDERS
0+
years
MULTIPLE SITES
Acute Lymphoblastic LeukemiaCMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01134575
  1. Houston, Texas
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Acute Lymphoblastic LeukemiaA Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576
  1. Brussels,
  2. Brussels,
  3. Brussels,
  4. Edegem,
  5. Ghent,
  6. Leuven,
  7. Leuven,
  8. Liège,
  9. Liège,
  10. Aalborg,
  11. Aarhus,
  12. Aarhus,
  13. Copenhagen,
  14. Copenhagen,
  15. Odense,
  16. Tallinn,
  17. Tallinn,
  18. Tartu,
  19. Tartu,
  20. Helsinki,
  21. Helsinki,
  22. Kuopio,
  23. Kuopio,
  24. Oulu,
  25. Oulu,
  26. Tampere,
  27. Tampere,
  28. Turku,
  29. Turku,
  30. Bielefeld,
  31. Bonn,
  32. Bremen,
  33. Hamburg,
  34. Krefeld,
  35. Mainz,
  36. München,
  37. Reykjavík,
  38. Dublin,
  39. Vilnius,
  40. Utrecht,
  41. Bergen,
  42. Bergen,
  43. Oslo,
  44. Oslo,
  45. Stavanger,
  46. Tromsø,
  47. Tromsø,
  48. Trondheim,
  49. Trondheim,
  50. Coimbra,
  51. Lisboa,
  52. Porto,
  53. Gothenburg,
  54. Gothenburg,
  55. Linköping,
  56. Linköping,
  57. Lund,
  58. Lund,
  59. Stockholm,
  60. Stockholm,
  61. Umeå,
  62. Umeå,
  63. Uppsala,
  64. Uppsala,
  65. Örebro,
  66. Aberdeen,
  67. Aberdeen,
  68. Belfast,
  69. Belfast,
  70. Birmingham,
  71. Birmingham,
  72. Bristol,
  73. Cambridge,
  74. Cardiff,
  75. Cardiff,
  76. Dundee,
  77. Edinburgh,
  78. Edinburgh,
  79. Glasgow,
  80. Glasgow,
  81. Leeds,
  82. Leeds,
  83. Leicester,
  84. Liverpool,
  85. Liverpool,
  86. London,
  87. London,
  88. Manchester,
  89. Manchester,
  90. Newcastle,
  91. Newcastle,
  92. Nottingham,
  93. Nottingham,
  94. Oxford,
  95. Oxford,
  96. Plymouth,
  97. Sheffield,
  98. Sheffield,
  99. Southampton,
  100. Stoke,
  101. Sutton,
ALL GENDERS
1 Year+
years
MULTIPLE SITES
Acute Lymphoblastic LeukemiaA Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784
  1. La Jolla, California
  2. La Jolla, California
  3. La Jolla, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Orange, California
  15. Orange, California
  16. Orange, California
  17. Palo Alto, California
  18. San Diego, California
  19. Stanford, California
  20. Stanford, California
  21. Stanford, California
  22. Aurora, Colorado
  23. Aurora, Colorado
  24. Aurora, Colorado
  25. New Haven, Connecticut
  26. Miami, Florida
  27. Orlando, Florida
  28. Orlando, Florida
  29. Orlando, Florida
  30. Orlando, Florida
  31. Atlanta, Georgia
  32. Atlanta, Georgia
  33. Atlanta, Georgia
  34. Atlanta, Georgia
  35. Atlanta, Georgia
  36. Atlanta, Georgia
  37. Augusta, Georgia
  38. Augusta, Georgia
  39. Chicago, Illinois
  40. Chicago, Illinois
  41. Chicago, Illinois
  42. Chicago, Illinois
  43. Chicago, Illinois
  44. Iowa City, Iowa
  45. Kansas City, Kansas
  46. Westwood, Kansas
  47. Louisville, Kentucky
  48. Louisville, Kentucky
  49. Baltimore, Maryland
  50. Baltimore, Maryland
  51. Baltimore, Maryland
  52. Boston, Massachusetts
  53. Boston, Massachusetts
  54. Boston, Massachusetts
  55. Ann Arbor, Michigan
  56. Detroit, Michigan
  57. Farmington Hills, Michigan
  58. Hackensack, New Jersey
  59. Hackensack, New Jersey
  60. New Brunswick, New Jersey
  61. Albuquerque, New Mexico
  62. Albuquerque, New Mexico
  63. Lake Success, New York
  64. Manhasset, New York
  65. New York, New York
  66. New York, New York
  67. New York, New York
  68. Rochester, New York
  69. Stony Brook, New York
  70. Stony Brook, New York
  71. Stony Brook, New York
  72. Stony Brook, New York
  73. Chapel Hill, North Carolina
  74. Chapel Hill, North Carolina
  75. Winston-Salem, North Carolina
  76. Cincinnati, Ohio
  77. Cleveland, Ohio
  78. Cleveland, Ohio
  79. Oklahoma City, Oklahoma
  80. Oklahoma City, Oklahoma
  81. Hershey, Pennsylvania
  82. Hershey, Pennsylvania
  83. Charleston, South Carolina
  84. Charleston, South Carolina
  85. Dallas, Texas
  86. Dallas, Texas
  87. Dallas, Texas
  88. Dallas, Texas
  89. Dallas, Texas
  90. Dallas, Texas
  91. Houston, Texas
  92. Salt Lake City, Utah
  93. Seattle, Washington
  94. Seattle, Washington
  95. Morgantown, West Virginia
  96. Morgantown, West Virginia
  97. Cordoba,
  98. Adelaide, South Australia
  99. Box Hill, Victoria
  100. Toronto, Ontario
  101. Guangzhou, Guangdong
  102. Zhengzhou, Henan
  103. Changchun, Jilin
  104. Beijing,
  105. Beijing,
  106. Beijing,
  107. Tianjin,
  108. Brno,
  109. Hradec Kralove,
  110. Praha 10,
  111. Helsinki,
  112. Helsinki,
  113. Dijon,
  114. Grenoble Cedex 09,
  115. Le Chesnay Cedex,
  116. Limoges Cedex,
  117. Marseille,
  118. Paris Cedex 10,
  119. Pierre Benite Cedex,
  120. Saint Priest en Jarez Cedex,
  121. Toulouse Cedex 9,
  122. Vandoeuvre-les-Nancy,
  123. Muenster, Nordrhein-westfalen
  124. Frankfurt,
  125. Heidelberg,
  126. Köln,
  127. Muenchen,
  128. Muenster,
  129. Muenster,
  130. Budapest,
  131. Debrecen,
  132. Cagliari, CA
  133. Cagliari, CA
  134. Cagliari, CA
  135. Meldola (FC), FC
  136. Bologna,
  137. Catania,
  138. Catania,
  139. Cona, Ferrara,
  140. Genova,
  141. Genova,
  142. Genova,
  143. Genova,
  144. Genova,
  145. Milano,
  146. Milano,
  147. Milano,
  148. Monza,
  149. Monza,
  150. Napoli,
  151. Napoli,
  152. Pavia,
  153. Ravenna,
  154. Ravenna,
  155. Ravenna,
  156. Udine,
  157. Udine,
  158. Nagoya, Aichi
  159. Nishinomiya-shi, Hyogo
  160. Sendai, Miyagi
  161. Osaka-city, Osaka
  162. Chuo-ku, Tokyo
  163. Akita,
  164. Fukuoka,
  165. Kanagawa,
  166. Hwasun-Gun, Jeonnam
  167. Seoul,
  168. Seoul,
  169. Rotterdam, South Holland
  170. Rotterdam, South Holland
  171. Gdansk,
  172. Lodz,
  173. Warsaw,
  174. Wroclaw,
  175. Singapore,
  176. Singapore,
  177. Badalona, Barcelona
  178. Salamanca, Castille AND LION
  179. Barcelona, Catalonia
  180. Palma de Mallorca, Mallorca
  181. Barcelona,
  182. Madrid,
  183. Madrid,
  184. Madrid,
  185. Murcia,
  186. Sevilla,
  187. Valencia,
  188. Lund,
  189. Stockholm,
  190. Kaohsiung,
  191. Taipei,
  192. Southampton, Hampshire
  193. Bristol,
  194. Hull,
  195. London,
  196. Manchester,
  197. Nottingham,
  198. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Official Title  ICMJE Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab
Brief Summary The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Detailed Description

Study Drugs:

CMC-544 is a monoclonal antibody (a substance that can locate and bind to cancer cells). It is designed to attach to C22, a molecule that is found on most cancer cells with ALL. This may cause the cancer cells to die.

Rituximab is a monoclonal antibody that is designed to attach to leukemia cells and activate a series of events that may cause the cancer cells to die.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will receive CMC-544 by vein over about 60 minutes on Day 1 of each study "cycle" or over 60 minutes at a lowered dose on Days 1, 8 and 15 of each cycle, depending on when you joined the study. No matter what dosing schedule you are on, you will receive the same total dosage of CMC-544. Each study cycle is about 3-4 weeks.

If the disease is not responding to the CMC-544 after 2 cycles, you will begin receiving rituximab. On Day 1 of Cycle 3, you will receive rituximab by vein over about 8 hours. On Day 2 of Cycle 3, you will receive CMC-544 alone by vein over about 60 minutes. Then, starting on Day 1 of Cycle 4, you will begin receiving rituximab by vein over about 8 hours and CMC-544 by vein over about 60 minutes at least 2-4 hours after you receive the rituximab. You will receive this combination 1 time every week.

Your dose of the study drug(s) may change depending on any side effects you may have.

Study Visits:

You will have study visits within 1 week before Day 1 of each study cycle. At each study visit, the following tests and procedures will be performed:

  • You will have a physical exam.
  • Your performance status will be recorded.
  • You will be asked how you are feeling and about any drugs you may be taking.
  • You will have an ECG before you receive treatment with CMC-544 (+ 2 days).
  • Blood (about 1 tablespoon) may be drawn to test how the study drug(s) may affect cancer cells before you receive the CMC-544 infusion.
  • If you are receiving rituximab and if you have a history of irregular heartbeat or chest pain (due to heart trouble), you will have ECGs performed before the start of the rituximab, once during the infusion, and within 2 hours after the infusion. Rituximab infusion will be stopped if you experience any serious episodes of irregular heartbeat.
  • If you are receiving rituximab, you may be examined for any signs or symptoms of bowel obstruction (blockage) and/or perforation (hole in the intestines, which may cause the contents to leak). Appropriate radiologic tests and surgical consults will be performed as needed.

Blood (about 1 tablespoon each time) will be drawn 1-3 times each week during Cycles 1 and 2, and at least 1 time every week during all other cycles for routine tests. Your doctor may decide to have more than 3 blood draws during Cycles 1 and 2.

You will have a bone marrow aspirate and/or biopsy between Days 14-21 (+/- 3 days) of Cycle 1 then every 1-2 cycles to check the status of the disease. You may have additional bone marrow aspirates and/or biopsies if your doctor feels it is necessary.

Length of Study:

You may receive CMC 544 with or without rituximab for up to 12 months. You will be taken off study if the disease gets worse or if you have intolerable side effects

Follow-up Visits:

You will have a follow-up visit 30 days after your last dose of the study drug(s). At this visit, you will be asked about any side effects you may be having. If you cannot make it to the clinic for this visit, it can be done over the phone with a member of the study staff. The phone call should last about 10 minutes.

This is an investigational study. Rituximab is FDA approved and commercially available for the treatment of lymphoid cancer. Neither CMC-544 nor the CMC-544/rituximab combination are FDA approved or commercially available. Their use in this study is investigational.

Up to 90 patients will take part in this study. All will be enrolled at MD Anderson.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:
The study started as a single arm study of Inotuzumab Ozogamicin administered at two different dose levels. The protocol was later amended to modify to weekly Inotuxumab Ozogamicin administration.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acute Lymphoblastic Leukemia
Intervention  ICMJE
  • Drug: CMC-544 (Inotuzumab Ozogamycin)

    First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle.

    Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.

  • Drug: Rituximab
    With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
    Other Name: rituxan
Study Arms  ICMJE
  • Experimental: Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2
    First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
    Interventions:
    • Drug: CMC-544 (Inotuzumab Ozogamycin)
    • Drug: Rituximab
  • Experimental: Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)
    CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
    Interventions:
    • Drug: CMC-544 (Inotuzumab Ozogamycin)
    • Drug: Rituximab
  • Experimental: Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2
    First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
    Interventions:
    • Drug: CMC-544 (Inotuzumab Ozogamycin)
    • Drug: Rituximab
Publications * Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr;13(4):403-11. doi: 10.1016/S1470-2045(11)70386-2. Epub 2012 Feb 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 30, 2019)
90
Original Estimated Enrollment  ICMJE
 (submitted: May 28, 2010)
40
Actual Study Completion Date  ICMJE April 18, 2018
Actual Primary Completion Date April 18, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Previously treated ALL (including Burkitt's lymphoma and lymphoblastic lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration. At least 10 patients in Salvage 1-2 will be treated to assess anti-ALL response more precisely.
  2. Age 16 years or older. Pediatric patients (<16 years old) will be allowed into the study after safety is established, that is at least 10 adult patients having received 1 or more cycles each.
  3. Zubrod performance status 0-3.
  4. Adequate liver function (bilirubin </= 1.5 mg/dL and Alanine transaminase (SGPT) or Aspartate transaminase (SGOT) </= 3 x upper limit of normal [ULN], unless considered due to tumor), and renal function (creatinine </= 2 mg/dL). Even if organ function abnormalities are considered due to tumor, the upper limit for bilirubin is </= 2.0 mg/dL and creatinine </= 3 mg/dL.
  5. Male and female patients who are of childbearing potential agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy. Female patients need a negative serum or urine pregnancy test within 14 days of study start (applies only if patient is of childbearing potential. Non-childbearing is defined as >/= 1 year postmenopausal or surgically sterilized).

Exclusion Criteria:

  1. Patient with active heart disease (NYHA class >/= 3 as assessed by history and physical examination).
  2. Patients with a cardiac ejection fraction (as measured by either Radionuclide angiography (MUGA) or echocardiogram) < 45% are excluded.
  3. Patients who receive other chemotherapy. Patients must have been off previous therapy for >/= 2 weeks and must have recovered from acute toxicity (to grade 1 or less) of all previous therapy prior to enrollment (consent signing). (Concurrent therapy for central nervous system [CNS] prophylaxis or treatment for CNS relapse is permitted). Treatment may start earlier if necessitated by the patient's medical condition (e.g. rapidly progressive disease) following discussion with the Principal Investigator.
  4. Prior allogeneic stem cell transplant in previous 4 months.
  5. Peripheral lymphoblasts > 50 x 10^9/L.
  6. Pregnant and breast-feeding patients are excluded.
  7. Patients with known hepatitis B are excluded.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01134575
Other Study ID Numbers  ICMJE 2009-0872
NCI-2011-01699 ( Registry Identifier: NCI CTRP )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party M.D. Anderson Cancer Center
Study Sponsor  ICMJE M.D. Anderson Cancer Center
Collaborators  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Investigators  ICMJE
Study Chair:Hagop Kantarjian, MDM.D. Anderson Cancer Center
PRS Account M.D. Anderson Cancer Center
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP